(Q35721055)

9 August 2017

1 reference

title

Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases (English)

1 reference

9 August 2017

cardiovascular disease

1 reference

1 reference

1 reference

Marie-Christine Alessi

1 reference

ORCID Public Data File 2021

author name string

Mavri A

series ordinal

1

1 reference

9 August 2017

Alessi MC

series ordinal

2

1 reference

9 August 2017

Juhan-Vague I

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Journal of Internal Medicine

9 August 2017

1 reference

9 August 2017

255

1 reference

9 August 2017

4

1 reference

9 August 2017

448-456

1 reference

Adaptation and maladaptation of the heart in diabetes: Part I: general concepts

9 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Hyperinsulinaemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmö Preventive Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Association between insulin resistance and carotid arteriosclerosis in subjects with normal fasting glucose and normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Plasminogen-activator inhibitor type 1 and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

A Forkhead/winged helix-related transcription factor mediates insulin-increased plasminogen activator inhibitor-1 gene transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Angiotensin and vascular fibrinolytic balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Adipose tissue as a buffer for daily lipid flux

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Extracellular matrix induced by TGFbeta impairs insulin signal transduction in 3T3-L1 preadipose cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01288.X

10.1046/J.1365-2796.2003.01288.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference